Which companies are the key players in the Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market?

Key players in the market include Novartis, Bristol-Myers Squibb, Merck & Co., AstraZeneca, Sanofi, Pfizer, Eli Lilly and Company, and Teva Pharmaceutical Industries. Read More

How does the market for Hypertension compare to that for Heart Failure in terms of valuation?

The market for Hypertension is projected to range from 1500.0 to 2300.0 USD Million, whereas the market for Heart Failure is expected to range from 1200.0 to 1800.0 USD Million. Read More

What are the projected valuations for the Oral and Intravenous routes of administration?

The projected valuation for the Oral route of administration is expected to range from 2560.0 to 4000.0 USD Million, while the Intravenous route is projected to range from 1280.0 to 1800.0 USD Million. Read More

What is the market size for Selective Angiotensin II Receptor Antagonists compared to Non-Selective Angiotensin II Receptor Antagonists?

The market size for Selective Angiotensin II Receptor Antagonists is projected to range from 2560.0 to 4000.0 USD Million, while Non-Selective Angiotensin II Receptor Antagonists are expected to range from 1714.86 to 2519.98 USD Million. Read More

What are the expected market valuations for different patient demographics in this market?

The expected market valuations are projected to be 2560.0 to 4000.0 USD Million for Adults, 1280.0 to 2000.0 USD Million for the Elderly, and 434.86 to 519.98 USD Million for Pediatric patients. Read More

Which distribution channels are expected to show the highest market valuations?

Retail Pharmacies are expected to show the highest market valuations, projected to range from 1800.0 to 2700.0 USD Million, compared to Hospital and Online Pharmacies. Read More

What is the projected market size for Chronic Kidney Disease applications?

The projected market size for Chronic Kidney Disease applications is expected to range from 774.86 to 1219.98 USD Million. Read More

Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market

Q: What is the projected market valuation for the Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market by 2035?

The projected market valuation for the Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market is expected to reach 6519.98 USD Million by 2035. Read More

Q: What was the overall market valuation for the Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market in 2024?

The overall market valuation for the Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market was 4274.86 USD Million in 2024. Read More

Q: What is the expected CAGR for the Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market during the forecast period 2025 - 2035?

The expected CAGR for the Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market during the forecast period 2025 - 2035 is 3.91%. Read More

ID: MRFR/Pharma/36951-HCR

100 Pages

Nidhi Mandole

Last Updated: May 21, 2026

Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Research Report By Route of Administration (Oral, Intravenous, Subcutaneous), By Therapeutic Area (Hypertension, Heart Failure, Chronic Kidney Disease), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Formulation Type (Tablets, Injections, Liquid Formulations) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)3.91%

2024 Market Size$ 4,274.86 Million

2025 Market Size$ 4,442.1 Million

2035 Market Size$ 6,519.98 Million

Key Players

Novartis

Bristol-Myers Squibb

Merck & Co.

AstraZeneca

Sanofi

Pfizer

Trends

Rising Demand for Innovative Therapies
Focus on Personalized Medicine
Regulatory Advancements and Safety Initiatives

Opportunities

Growing Geriatric Population
Advancements in Drug Development
Increasing Prevalence of Hypertension

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Million)
  1. 4.1.1 Hypertension
  2. 4.1.2 Heart Failure
  3. 4.1.3 Diabetic Nephropathy
  4. 4.1.4 Chronic Kidney Disease
2. 4.2 Healthcare, BY Route of Administration (USD Million)
  1. 4.2.1 Oral
  2. 4.2.2 Intravenous
  3. 4.2.3 Subcutaneous
3. 4.3 Healthcare, BY Drug Class (USD Million)
  1. 4.3.1 Selective Angiotensin II Receptor Antagonists
  2. 4.3.2 Non-Selective Angiotensin II Receptor Antagonists
4. 4.4 Healthcare, BY Patient Demographics (USD Million)
  1. 4.4.1 Adults
  2. 4.4.2 Elderly
  3. 4.4.3 Pediatric
5. 4.5 Healthcare, BY Distribution Channel (USD Million)
  1. 4.5.1 Hospital Pharmacies
  2. 4.5.2 Retail Pharmacies
  3. 4.5.3 Online Pharmacies
6. 4.6 Healthcare, BY Region (USD Million)
  1. 4.6.1 North America
    1. 4.6.1.1 US
    2. 4.6.1.2 Canada
  2. 4.6.2 Europe
    1. 4.6.2.1 Germany
    2. 4.6.2.2 UK
    3. 4.6.2.3 France
    4. 4.6.2.4 Russia
    5. 4.6.2.5 Italy
    6. 4.6.2.6 Spain
    7. 4.6.2.7 Rest of Europe
  3. 4.6.3 APAC
    1. 4.6.3.1 China
    2. 4.6.3.2 India
    3. 4.6.3.3 Japan
    4. 4.6.3.4 South Korea
    5. 4.6.3.5 Malaysia
    6. 4.6.3.6 Thailand
    7. 4.6.3.7 Indonesia
    8. 4.6.3.8 Rest of APAC
  4. 4.6.4 South America
    1. 4.6.4.1 Brazil
    2. 4.6.4.2 Mexico
    3. 4.6.4.3 Argentina
    4. 4.6.4.4 Rest of South America
  5. 4.6.5 MEA
    1. 4.6.5.1 GCC Countries
    2. 4.6.5.2 South Africa
    3. 4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Merck & Co. (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 AstraZeneca (GB)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Sanofi (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Pfizer (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Eli Lilly and Company (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Teva Pharmaceutical Industries (IL)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY APPLICATION
4. 6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 US MARKET ANALYSIS BY DRUG CLASS
6. 6.6 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
7. 6.7 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
8. 6.8 CANADA MARKET ANALYSIS BY APPLICATION
9. 6.9 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
10. 6.10 CANADA MARKET ANALYSIS BY DRUG CLASS
11. 6.11 CANADA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
12. 6.12 CANADA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
13. 6.13 EUROPE MARKET ANALYSIS
14. 6.14 GERMANY MARKET ANALYSIS BY APPLICATION
15. 6.15 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
16. 6.16 GERMANY MARKET ANALYSIS BY DRUG CLASS
17. 6.17 GERMANY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
18. 6.18 GERMANY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
19. 6.19 UK MARKET ANALYSIS BY APPLICATION
20. 6.20 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
21. 6.21 UK MARKET ANALYSIS BY DRUG CLASS
22. 6.22 UK MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
23. 6.23 UK MARKET ANALYSIS BY DISTRIBUTION CHANNEL
24. 6.24 FRANCE MARKET ANALYSIS BY APPLICATION
25. 6.25 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
26. 6.26 FRANCE MARKET ANALYSIS BY DRUG CLASS
27. 6.27 FRANCE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
28. 6.28 FRANCE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
29. 6.29 RUSSIA MARKET ANALYSIS BY APPLICATION
30. 6.30 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
31. 6.31 RUSSIA MARKET ANALYSIS BY DRUG CLASS
32. 6.32 RUSSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
33. 6.33 RUSSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
34. 6.34 ITALY MARKET ANALYSIS BY APPLICATION
35. 6.35 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
36. 6.36 ITALY MARKET ANALYSIS BY DRUG CLASS
37. 6.37 ITALY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
38. 6.38 ITALY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
39. 6.39 SPAIN MARKET ANALYSIS BY APPLICATION
40. 6.40 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
41. 6.41 SPAIN MARKET ANALYSIS BY DRUG CLASS
42. 6.42 SPAIN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
43. 6.43 SPAIN MARKET ANALYSIS BY DISTRIBUTION CHANNEL
44. 6.44 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
45. 6.45 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
46. 6.46 REST OF EUROPE MARKET ANALYSIS BY DRUG CLASS
47. 6.47 REST OF EUROPE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
48. 6.48 REST OF EUROPE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
49. 6.49 APAC MARKET ANALYSIS
50. 6.50 CHINA MARKET ANALYSIS BY APPLICATION
51. 6.51 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
52. 6.52 CHINA MARKET ANALYSIS BY DRUG CLASS
53. 6.53 CHINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
54. 6.54 CHINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
55. 6.55 INDIA MARKET ANALYSIS BY APPLICATION
56. 6.56 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
57. 6.57 INDIA MARKET ANALYSIS BY DRUG CLASS
58. 6.58 INDIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
59. 6.59 INDIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
60. 6.60 JAPAN MARKET ANALYSIS BY APPLICATION
61. 6.61 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
62. 6.62 JAPAN MARKET ANALYSIS BY DRUG CLASS
63. 6.63 JAPAN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
64. 6.64 JAPAN MARKET ANALYSIS BY DISTRIBUTION CHANNEL
65. 6.65 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
66. 6.66 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
67. 6.67 SOUTH KOREA MARKET ANALYSIS BY DRUG CLASS
68. 6.68 SOUTH KOREA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
69. 6.69 SOUTH KOREA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
70. 6.70 MALAYSIA MARKET ANALYSIS BY APPLICATION
71. 6.71 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
72. 6.72 MALAYSIA MARKET ANALYSIS BY DRUG CLASS
73. 6.73 MALAYSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
74. 6.74 MALAYSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
75. 6.75 THAILAND MARKET ANALYSIS BY APPLICATION
76. 6.76 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
77. 6.77 THAILAND MARKET ANALYSIS BY DRUG CLASS
78. 6.78 THAILAND MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
79. 6.79 THAILAND MARKET ANALYSIS BY DISTRIBUTION CHANNEL
80. 6.80 INDONESIA MARKET ANALYSIS BY APPLICATION
81. 6.81 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
82. 6.82 INDONESIA MARKET ANALYSIS BY DRUG CLASS
83. 6.83 INDONESIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
84. 6.84 INDONESIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
85. 6.85 REST OF APAC MARKET ANALYSIS BY APPLICATION
86. 6.86 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
87. 6.87 REST OF APAC MARKET ANALYSIS BY DRUG CLASS
88. 6.88 REST OF APAC MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
89. 6.89 REST OF APAC MARKET ANALYSIS BY DISTRIBUTION CHANNEL
90. 6.90 SOUTH AMERICA MARKET ANALYSIS
91. 6.91 BRAZIL MARKET ANALYSIS BY APPLICATION
92. 6.92 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
93. 6.93 BRAZIL MARKET ANALYSIS BY DRUG CLASS
94. 6.94 BRAZIL MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
95. 6.95 BRAZIL MARKET ANALYSIS BY DISTRIBUTION CHANNEL
96. 6.96 MEXICO MARKET ANALYSIS BY APPLICATION
97. 6.97 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
98. 6.98 MEXICO MARKET ANALYSIS BY DRUG CLASS
99. 6.99 MEXICO MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
100. 6.100 MEXICO MARKET ANALYSIS BY DISTRIBUTION CHANNEL
101. 6.101 ARGENTINA MARKET ANALYSIS BY APPLICATION
102. 6.102 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
103. 6.103 ARGENTINA MARKET ANALYSIS BY DRUG CLASS
104. 6.104 ARGENTINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
105. 6.105 ARGENTINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG CLASS
109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
111. 6.111 MEA MARKET ANALYSIS
112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY DRUG CLASS
115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY DISTRIBUTION CHANNEL
117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY DRUG CLASS
120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
122. 6.122 REST OF MEA MARKET ANALYSIS BY APPLICATION
123. 6.123 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
124. 6.124 REST OF MEA MARKET ANALYSIS BY DRUG CLASS
125. 6.125 REST OF MEA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
126. 6.126 REST OF MEA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
128. 6.128 RESEARCH PROCESS OF MRFR
129. 6.129 DRO ANALYSIS OF HEALTHCARE
130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
133. 6.133 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
134. 6.134 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
135. 6.135 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
136. 6.136 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
137. 6.137 HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE)
138. 6.138 HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Million)
139. 6.139 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
140. 6.140 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Million)
141. 6.141 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
142. 6.142 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
  3. 7.2.3 BY DRUG CLASS, 2026-2035 (USD Million)
  4. 7.2.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.2.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.3.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
  3. 7.3.3 BY DRUG CLASS, 2026-2035 (USD Million)
  4. 7.3.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.3.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.4.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
  3. 7.4.3 BY DRUG CLASS, 2026-2035 (USD Million)
  4. 7.4.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.4.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.5.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
  3. 7.5.3 BY DRUG CLASS, 2026-2035 (USD Million)
  4. 7.5.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.5.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.6.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
  3. 7.6.3 BY DRUG CLASS, 2026-2035 (USD Million)
  4. 7.6.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.6.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.7.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
  3. 7.7.3 BY DRUG CLASS, 2026-2035 (USD Million)
  4. 7.7.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.7.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.8.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
  3. 7.8.3 BY DRUG CLASS, 2026-2035 (USD Million)
  4. 7.8.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.8.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.9.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
  3. 7.9.3 BY DRUG CLASS, 2026-2035 (USD Million)
  4. 7.9.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.9.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.10.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
  3. 7.10.3 BY DRUG CLASS, 2026-2035 (USD Million)
  4. 7.10.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.10.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.11.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
  3. 7.11.3 BY DRUG CLASS, 2026-2035 (USD Million)
  4. 7.11.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.11.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.12.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
  3. 7.12.3 BY DRUG CLASS, 2026-2035 (USD Million)
  4. 7.12.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.12.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.13.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
  3. 7.13.3 BY DRUG CLASS, 2026-2035 (USD Million)
  4. 7.13.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.13.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.14.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
  3. 7.14.3 BY DRUG CLASS, 2026-2035 (USD Million)
  4. 7.14.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.14.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.15.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
  3. 7.15.3 BY DRUG CLASS, 2026-2035 (USD Million)
  4. 7.15.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.15.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.16.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
  3. 7.16.3 BY DRUG CLASS, 2026-2035 (USD Million)
  4. 7.16.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.16.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.17.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
  3. 7.17.3 BY DRUG CLASS, 2026-2035 (USD Million)
  4. 7.17.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.17.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.18.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
  3. 7.18.3 BY DRUG CLASS, 2026-2035 (USD Million)
  4. 7.18.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.18.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.19.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
  3. 7.19.3 BY DRUG CLASS, 2026-2035 (USD Million)
  4. 7.19.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.19.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.20.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
  3. 7.20.3 BY DRUG CLASS, 2026-2035 (USD Million)
  4. 7.20.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.20.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.21.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
  3. 7.21.3 BY DRUG CLASS, 2026-2035 (USD Million)
  4. 7.21.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.21.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.22.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
  3. 7.22.3 BY DRUG CLASS, 2026-2035 (USD Million)
  4. 7.22.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.22.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.23.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
  3. 7.23.3 BY DRUG CLASS, 2026-2035 (USD Million)
  4. 7.23.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.23.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.24.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
  3. 7.24.3 BY DRUG CLASS, 2026-2035 (USD Million)
  4. 7.24.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.24.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.25.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
  3. 7.25.3 BY DRUG CLASS, 2026-2035 (USD Million)
  4. 7.25.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.25.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.26.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
  3. 7.26.3 BY DRUG CLASS, 2026-2035 (USD Million)
  4. 7.26.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.26.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.27.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
  3. 7.27.3 BY DRUG CLASS, 2026-2035 (USD Million)
  4. 7.27.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.27.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.28.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
  3. 7.28.3 BY DRUG CLASS, 2026-2035 (USD Million)
  4. 7.28.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.28.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.29.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
  3. 7.29.3 BY DRUG CLASS, 2026-2035 (USD Million)
  4. 7.29.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.29.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.30.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
  3. 7.30.3 BY DRUG CLASS, 2026-2035 (USD Million)
  4. 7.30.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.30.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Segmentation

Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market By Application (USD Million, 2022-2035)

Hypertension
Heart Failure
Diabetic Nephropathy
Chronic Kidney Disease

Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market By Route of Administration (USD Million, 2022-2035)

Oral
Intravenous
Subcutaneous

Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market By Drug Class (USD Million, 2022-2035)

Selective Angiotensin II Receptor Antagonists
Non-Selective Angiotensin II Receptor Antagonists

Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market By Patient Demographics (USD Million, 2022-2035)

Adults
Elderly
Pediatric

Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market By Distribution Channel (USD Million, 2022-2035)

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035